Brief: Cipla Says Invagen Has Received Establishment Inspection Report From USFDA, Indicating Closure Of Inspection
04/08/2026 04:29
BRIEF-Cipla Says Invagen Has Received Establishment Inspection Report From USFDA, Indicating Closure Of Inspection Aug 4 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA- INVAGEN HAS RECEIVED ESTABLISHMENT INSPECTION REPORT FROM USFDA, INDICATING CLOSURE OF INSPECTION
Source text: ID:nnAZN4TBMIX
Further company coverage: CIPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate